Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

1.73USD
18 Aug 2017
Change (% chg)

$0.02 (+1.17%)
Prev Close
$1.71
Open
$1.69
Day's High
$1.78
Day's Low
$1.68
Volume
197,942
Avg. Vol
176,417
52-wk High
$3.31
52-wk Low
$1.30

IDRA.OQ

Chart for IDRA.OQ

About

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting... (more)

Overall

Beta: 2.18
Market Cap(Mil.): $258.86
Shares Outstanding(Mil.): 149.63
Dividend: --
Yield (%): --

Financials

  IDRA.OQ Industry Sector
P/E (TTM): -- 79.67 32.70
EPS (TTM): -0.35 -- --
ROI: -70.35 2.87 14.88
ROE: -71.53 5.20 16.12

BRIEF-Idera Pharmaceuticals files for‍​ mixed shelf

* Idera pharmaceuticals inc files for‍​ mixed shelf of up to $250 million - sec filing‍​ Source text for Eikon: Further company coverage:

Aug 10 2017

BRIEF-Idera Pharmaceuticals Q2 loss per share $0.14

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

Aug 07 2017

BRIEF-FDA gives "orphan drug" status to Idera's skin cancer drug

* Idera announces FDA orphan drug designation for IMO-2125 for the treatment of melanoma

Jun 22 2017

HGGC to buy majority stake in Idera, values firm over $1 billion

SAN FRANCISCO HGGC has agreed to take a majority stake in database software firm Idera, valuing the company at roughly $1.125 billion including debt, the private equity firm said in a statement.

May 31 2017

UPDATE 1-HGGC to buy majority stake in Idera, values firm over $1 bln

SAN FRANCISCO, May 31 HGGC has agreed to take a majority stake in database software firm Idera, valuing the company at roughly $1.125 billion including debt, the private equity firm said in a statement.

May 31 2017

HGGC to buy majority stake in Idera, values firm over $1 bln: sources

SAN FRANCISCO, May 31 Private equity firm HGGC has agreed to take a majority stake in database software firm Idera, valuing the company at roughly $1.125 billion including debt, according to sources familiar with the matter.

May 31 2017

BRIEF-Idera Pharmaceuticals reports Q1 loss per share $0.10

* Idera Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

May 04 2017

BRIEF-Idera Pharmaceuticals announces organizational update

* Idera Pharmaceuticals announces organizational update Source text for Eikon: Further company coverage:

Apr 18 2017

BRIEF-Idera Pharmaceuticals advances investigational treatment for unmet need in anti-PD-1 refractory metastatic melanoma

* Idera Pharmaceuticals advances investigational treatment – intratumoral IMO-2125 in combination with ipilimumab - for unmet need in anti-PD-1 refractory metastatic melanoma

Apr 11 2017

BRIEF-Idera Pharmaceuticals reports Q4 earnings per share $0.01

* Idera Pharmaceuticals reports fourth quarter and year end 2016 financial results and provides corporate update

Mar 15 2017

Earnings vs. Estimates